FDA D.I.S.C.O.: L-glutamine for sickle cell disease. FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease.

FDA D.I.S.C.O.: L-glutamine for sickle cell disease

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Science

Share FDA D.I.S.C.O.: L-glutamine for sickle cell disease

Sign up to save your podcasts

FDA D.I.S.C.O.: L-glutamine for sickle cell disease

FDA D.I.S.C.O.: L-glutamine for sickle cell disease